IDH2 and central nervous system cancer: In 2009, a series of seminal studies identified isocitrate dehydrogenase (IDH) mutations in gliomas [3, 4] and they were shown to carry favorable prognosis compared to their IDH wild-type (IDHwt) counterparts.